Metraipolis › archive › dc_72eacfe148d0
Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg — Europe PMC PMID:41843763
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41843763
- DOI
- 10.1093/ecco-jcc/jjag011
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T06:57:13.913Z
- SHA-256 of the archived text
46f383134938092047a70340ffa78828e47c9aca4997b7fa578eeb6157d3de67- Stable URL of this page
https://metraipolis.com/documento/dc_72eacfe148d0
How to cite
Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg — Europe PMC PMID:41843763 — Europe PMC (en), https://europepmc.org/article/MED/41843763 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_72eacfe148d0 (Metraipolis archive dc_72eacfe148d0, sha256 46f383134938092047a70340ffa78828e47c9aca4997b7fa578eeb6157d3de67)
BibTeX
@misc{dc72eacfe148d0,
title = {Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg — Europe PMC PMID:41843763},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41843763},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_72eacfe148d0; sha256 46f383134938092047a70340ffa78828e47c9aca4997b7fa578eeb6157d3de67},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41843763. Agents can read the archived copy with the MCP tool read_document.